Evolocumab 140 MG/ML

DRUG6 trials

Sponsors

Insel Gruppe AG, University Hospital Bern, University of Campinas, Brazil, Assistance Publique - Hôpitaux de Paris, First Affiliated Hospital Xi'an Jiaotong University, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Conditions

Acute Coronary SyndromeCerebral AtherosclerosisCoronary DiseaseDiabetes Mellitus, Type 2Dyslipidemia Associated With Type II Diabetes MellitusHypertension ArterialLow-Density-Lipoprotein-Type [LDL] HyperlipoproteinemiaNSTEMI - Non-ST Segment Elevation MI

Phase 3

EVOlocumab for Early Reduction of LDL-cholesterol Levels in Patients With Acute Coronary Syndromes (EVOPACS)

CompletedNCT03287609

Insel Gruppe AG, University Hospital BernAcute Coronary Syndrome

Start: 2018-01-23End: 2019-08-07Updated: 2019-08-14

Phase 4

EXpanded Combination of Evolocumab Plus Empagliflozin on Diabetes: EXCEED-BHS3 Trial

CompletedNCT03932721

University of Campinas, BrazilDiabetes Mellitus, Type 2, Dyslipidemia Associated With Type II Diabetes Mellitus, Hypertension Arterial

Start: 2018-10-01End: 2021-10-30Updated: 2023-03-09

Evolocumab or Normal Strategies to Reach LDL Objectives in Acute Myocardial Infarction Upbound to PCI

Active, not recruitingNCT04951856

Assistance Publique - Hôpitaux de ParisNSTEMI - Non-ST Segment Elevation MI, STEMI - ST Elevation Myocardial Infarction

Start: 2021-09-29End: 2028-05-22Target: 2166Updated: 2025-12-17

High-Resolution Assessment of Extracranial Plaques in a Multiple Centers Evolocumab Randomized Study

Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyCerebral Atherosclerosis

Start: 2022-11-09End: 2024-10-01Target: 200Updated: 2023-12-11

Effect of Early Initiation of Evolocumab on Lipid Profiles Changes in Patients With ACS Undergoing PCI

CompletedNCT05661552

Yonsei UniversityLow-Density-Lipoprotein-Type [LDL] Hyperlipoproteinemia

Start: 2022-12-01End: 2025-02-05Updated: 2025-03-13

Unknown Phase

In-hospital Initiation of PCSK9 Inhibitor in Patients With Acute Myocardial Infarction

CompletedNCT05184530

First Affiliated Hospital Xi'an Jiaotong UniversityCoronary Disease

Start: 2016-01-31End: 2021-12-31Updated: 2022-01-11

Related Papers

Effect of Early Initiation of Evolocumab on Lipid Profiles Changes in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention.

2026-01-06

In-hospital initiation of PCSK9 inhibitor and short-term lipid control in patients with acute myocardial infarction.

2022-10-2412 citations

Rationale and design of the expanded combination of evolocumab plus empagliflozin in diabetes: EXCEED-BHS3 trial

Therapeutic Advances in Chronic Disease2020-01-0113 citations

Evolocumab for Early Reduction of LDL Cholesterol Levels in Patients With Acute Coronary Syndromes (EVOPACS).

2019-08-31183 citations